We present a multicenter retrospective, observational case series from two U.S. medical centers describing five patients with refractory hypomagnesemia who experienced significant improvement following initiation of SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and familial primary hypomagnesemia.